Share Price | MiNK Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does MiNK Therapeutics, Inc. do?

Overview:MiNK Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)Market cap: USD 29.85 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.09Return on Equity: 40.99%Price to Book: -1.37Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Q: Is MiNK Therapeutics, Inc. technically bullish or bearish?

As of 29 July 2025, the technical trend for MiNK Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness and weekly Bollinger Bands also showing bullish signals. However, the MACD on a weekly basis is mildly bearish, and the RSI on a monthly basis is bearish, which tempers the overall bullish outlook. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 120.26% compared to the S&P 500's 12.22%, and over the past year, it has returned 107.43% against the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

13.6 k

Shareholding (Sep 2025)

FII

0.58%

Held by 8 FIIs

DII

98.43%

Held by 1 DIIs

Promoter

0.00%

How big is MiNK Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, MiNK Therapeutics, Inc. has a market capitalization of 29.85 million, with net sales of 0.00 million and a net profit of -9.74 million over the last four quarters. As of Dec 24, shareholder's funds are -19.59 million and total assets are 5.72 million.

View full answer

What does MiNK Therapeutics, Inc. do?

22-Jun-2025

MiNK Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $29.85 million. Key metrics include a return on equity of 40.99% and no dividend yield.

View full answer

Is MiNK Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 29, 2025, MiNK Therapeutics, Inc. shows a mildly bullish trend with daily moving averages supporting this outlook, despite a mildly bearish MACD and bearish RSI, while significantly outperforming the S&P 500 with a year-to-date return of 120.26% compared to 12.22%.

View full answer

Compare MiNK Therapeutics, Inc. with Similar Stocks

Miromatrix Medical, Inc.Portage Biotech, Inc.Passage Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 58 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.63

Return on Equity

83.94%

Price to Book

-4.27

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.97%

6 Months

-16.64%

1 Year

-8.4%

2 Years

22.58%

3 Years

396.4%

4 Years

-65.67%

5 Years

0.0%

MiNK Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

17.03%

EBIT to Interest (avg)

-21.15

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.08%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.33

EV to EBIT

-3.29

EV to EBITDA

-3.37

EV to Capital Employed

-1.55

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (0.99%)

Foreign Institutions

Held by 8 Foreign Institutions (0.58%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -55.56% vs 56.45% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-2.90",
          "chgp": "-24.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "-0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-2.70",
          "chgp": "-55.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.00% vs 19.64% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.40",
          "val2": "-22.70",
          "chgp": "54.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "0.30",
          "chgp": "-266.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.80",
          "val2": "-22.50",
          "chgp": "52.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.60

-2.90

-24.14%

Interest

0.00

Exceptional Items

-0.40

-0.20

-100.00%

Consolidate Net Profit

-4.20

-2.70

-55.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -55.56% vs 56.45% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.40

-22.70

54.19%

Interest

0.00

Exceptional Items

-0.50

0.30

-266.67%

Consolidate Net Profit

-10.80

-22.50

52.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 52.00% vs 19.64% in Dec 2023

All Annual Results

Company CV

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

MiNK Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is MiNK Therapeutics, Inc.?

Watch in Real-Time

What does MiNK Therapeutics, Inc. do?

Is MiNK Therapeutics, Inc. technically bullish or bearish?

Compare MiNK Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About MiNK Therapeutics, Inc.

Company Coordinates